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INTRODUCTION
Waldeyer´s ring is the second most




lymphomas (NHL) found in Waldeyer´s ring, the
tonsils are the primary location for the disease
in 80% of the cases.
2 
Most of them have recently
been recognized as MALT (mucosa-associated
lymphoid tissue),
3
 which show a progression
from low-grade to high-grade lymphoma
indistinguishable from other high-grade B-cell
lymphomas. The origin of the tumor may be
defined in 30-40% of cases, but only if residual
areas of low-grade lymphoma can be identified
in the biopsy specimens.
1, 4
In the last few years, there have been many
reports that favor aggressive systemic treatment
with chemotherapy and radiotherapy, even for
such well-localized lymphomas, avoiding the
need for tonsillectomy of the normal tonsil.
2,5,6
CASE REPORT
We report six cases of primary tonsillar
non-Hodgkin´s lymphoma, diagnosed between
March 1986 and July 1996. There were five
male patients and one female, with ages
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ranging from 20 to 64 years old (a median of
42 years old) (Table 1). In accordance with the
Working Formulation classification, there were
two diffuse large cell lymphomas, two diffuse
mixed small and large cell lymphomas, one
small lymphocytic lymphoma and one could not
be classified due to intense tonsil necrosis. At
the time of this study, embedded paraffin
specimens were only available for three cases
(cases 1, 3 and 4). They were reviewed
according to the REAL classification
3
 and the
diagnoses were maintained. Case 6 would
probably be reclassified as MALT lymphoma
(Table 1).
Four patients were staged as IIA (palatine
tonsil and cervical adenomegaly) and two were
staged as IA or B.
7
 All of them were negative
for HIV.
The patients were treated with six cycles
of chemotherapy (two cases with BACOP, one
with CHOP-Bleo and the three more recent cases
with ProMACE-CytaBOM) and all patients
except case 6 received cervical radiotherapy
(4000 cGy), preferentially between the third
and fourth cycles of chemotherapy.
All patients achieved remission with
combined therapy. Five patients were in
complete remission, having been followed up
for 15, 17, 20, 61 and 135 months by October
1997. One of them was lost from the follow-up
at 29 months after diagnosis (case 2).
Our first cases were treated with
conventional schedules (CHOP-Bleo and
BACOP) without CNS prophylaxis. The later
three cases (one case of fast growing tumor and
tonsil necrosis and two cases of large cell
lymphoma) were treated with ProMACE-
CytaBOM, and were submitted to four monthly
intrathecal infusions of methotrexate and
dexametasone, because the disease was close
to the CNS and their histology suggested a more
aggressive disease, with a higher probability
of relapse.
DISCUSSION
None of our patients were submitted to
tonsillectomy of the normal palatine tonsil
because we believed that cervical radiotherapy
was enough to prevent local relapse.
2,5,6
Based on the fact that a proportion of
patients with tonsillar NHL may relapse in the
gastrointestinal tract,
1
 we have been performing
endoscopic examinations and biopsies of the
stomach every 6 months up until five years after
diagnosis.
The results from our patients are in
accordance with Endo et al,
2
 who analyzed 38
cases of primary tonsillar NHL and concluded
that in patients with stage I or II tonsillar
lymphomas with bulky tumor mass,
chemotherapy followed by radiotherapy might
be the choice of treatment.
Moreover, Barista et al
8
 believed that stage
II tonsillar NHL with aggressive histology could
be treated with a combined therapy. In fact,
the grades of malignancy, stage and tumor
burden are the most important prognostic factors
in tonsillar NHL.
2,8
However, considering our small number of
Table 1 – Patients, histologic subtype, treatment and follow-up
Patient Age Sex Stage Histology Treatment Follow-up Risk factor
1 44 M IB Lymphoma+ Necrosis Promace-Cytabom + RT CR 15+ Low
2 40 M IIA DSLCL BACOP + RT CR 29* Low
3 36 M IIA DLCL Promace-Cytabom + RT CR 17+ Low
4 56 M IIA DLCL Promace- Cytabom + RT CR 20+ Low
5 20 M IA DSLCL CHOP-Bleo + RT CR 61+ Low
6 64 F IIA SLL BACOP CR 135+ —
* lost from follow-up; CR = complete remission; DSLCL = diffuse small and large cell lymphoma; DLCL = diffuse large cell lymphoma;
SLL = small lymphocytic lymphoma
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patients, we decided to apply the international
index of the International Non-Hodgkin´s
Lymphoma Factors Project 
9,10 
for the five aggressive
NHL included in this report (Table 2). All of them
were scored as low-risk (Table 1), with probable
disease-free survival of 70% after five years.
Our data agreed with previous reports that
suggested that primary tonsillar high-grade B-
cell NHL has a good prognosis if aggressively
treated with combined chemotherapy and
radiotherapy.
One possible explanation for this behavior
is the origin of the tumor, coming from a
localized and non-aggressive mucosa-
associated lymphoid tissue (MALT) lymphoma.
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RESUMO
Contexto: Muitos trabalhos têm proposto tratamento sistêmico agressivo com quimioterapia e radioterapia para os linfomas
de tonsila palatina, mesmo tratando-se de tumores bem localizados, sem a necessidade de amidalectomia contralateral.
Relato de Caso: Nós relatamos seis casos de linfoma primário de tonsila palatina, com idade mediana de 42 anos. Havia
dois casos de linfoma difuso de grandes células, dois casos de linfoma de pequenas e grandes células, um caso de linfoma
linfocítico de pequenas células e um caso indeterminado. Foram tratados com seis ciclos de quimioterapia e radioterapia
cervical. Todos os pacientes atingiram remisão completa mantida. Nossos dados estão de acordo com relatos prévios que
sugerem que os linfomas de células B têm bom prognóstico se agressivamente tratados.
Palavras-chave: Linfoma não-Hodgkin. Tonsila palatina. Tratamento prognóstico.
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